(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
13 June 2013 (13.06.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/083817 A1

(51) International Patent Classification:
A61K 47/48 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/EP2012/074867

(22) International Filing Date:
7 December 2012 (07.12.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/568,640 8 December 2011 (08.12.2011) US
61/722,367 5 November 2012 (05.11.2012) US

(71) Applicants *(for all designated States except US)*: **BIOTEST AG** [DE/DE]; Landsteinerstrasse 5, 63303 Dreieich (DE). **IMMUNOGEN, INC.** [US/US]; 830 Winter Street, Waltham, Massachusetts 02451 (US).

(72) Inventors; and
(71) Applicants *(for US only)*: **SCHULZ, Gregor** [DE/DE]; Rosenstrasse 13, 79224 Umkirch (DE). **OSTERROTH, Frank** [DE/DE]; Boellstrasse 24, 63128 Dietzenbach (DE). **HAEDER, Thomas** [DE/DE]; Staffordstrasse 39a, 63303 Dreieich (DE). **BRUECHER, Christoph** [DE/DE]; Unter den Tannen 3a, 65760 Eschborn (DE). **NIEMANN, Gabriele** [DE/DE]; Kraichgaustrasse 55, 75045 Walzbachtal (DE). **ENGLING, Andre** [DE/DE]; Lindenstrasse 27a, 61352 Bad Homburg (DE). **UHEREK, Christoph** [DE/DE]; Lachenwoerthweg 6, 63500 Seligenstadt (DE). **DAELKEN, Benjamin** [DE/DE]; Eleonore-Sterling-Strasse 40, 60433 Frankfurt am Main (DE). **WARTENBERG-DEMAND, Andrea** [DE/DE]; Alsfelder Strasse 20-22, 34637 Schrecksbach (DE). **ZUBER, Chantal** [DE/DE]; Welserweg 9/1, 89077 Ulm (DE). **GUTSCHER, Marcus** [DE/DE]; Theodor-Heuss Strasse 53, 63225 Langen (DE). **BERNOESTER, Katrin** [DE/DE]; Obergasse 75, 65207 Wiesbaden (DE). **KOENIG, Martin** [DE/DE]; Traunsteinerstrasse 14, 65205 Wiesbaden (DE).

(74) Agent: **JEFFREY NICHOLAS DANIELS**; Page White & Farrer, Bedford House, John Street, London Greater London WC1N 2BF (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

WO 2013/083817 A1

(54) Title: USES OF IMMUNOCONJUGATES TARGETING CD138

(57) Abstract: Provided is a method for treating a disease associated with target cells expressing CD 138 comprising: administering to a subject, in particular a human subject, in need thereof an immunoconjugate comprising at least one engineered targeting antibody targeting CD138 expressing cells, and at least one effector molecule, wherein said engineered targeting antibody is functionally attached to said effector molecule to form said immunoconjugate, wherein preferably at least a part of the engineered targeting antibody confers lgG4 isotype properties, wherein the immunoconjugate is administered in a multiple dose regimen comprising at least two doses, wherein the aggregate dose administered within an active treatment cycle is an aggregate maximum tolerable dose (AMTD) or a fraction of the AMTD and wherein said AMTD and/or said fraction exceeds the dose resulting in dose limiting toxicity (DLT) when the immunoconjugate is administered as a single dose, including as part of a multiple single dose regimen and/or exceeds the maximum tolerable dose (MTD) when the immunoconjugate is administered as a single dose, including as part of a multiple single dose regimen within said active treatment cycle.